Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Stopped early · Phase 1
Conditions studied: Lymphoma
In brief
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.
Key facts
- Study ID
- NCT00033423
- Run by
- University of Alabama at Birmingham
- People needed
- 18
- Starts
- 2001-08-01
- Expected to finish
- 2009-05-01
- Last updated by the study team
- 2013-12-13
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham — Birmingham, Alabama, United States
- Stanford Comprehensive Cancer Center - Stanford — Stanford, California, United States
- Mayo Clinic Cancer Center — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.